We would love to hear your thoughts about our site and services, please take our survey here.
Going back to this thread we have SRA737 Final Data readouts from 2 completed clinical studies due out this week?
Thoth you raised a good point that if the data is good then it could be 30p to a quid once the analysts crunch the numbers.
Otherwise is always a rub and in this case
leading expert warned that a limited supply of the raw ingredients needed for Covid vaccines such as Pfizer's risks leaving much of the world's population unprotected. The other rub is convincing people to take it. I won’t as I have already had covid twice abd last time I had a flu jab I reacted really badly and put my shoulder out of action for 12 months.
Thoth I agree something is building, some huge buys over the last few weeks; it’s either II or BO. Not sure which one but one of them. Some really huge swings in price action as well. There is a lot of news flow in a short space of time. SAR has a diverse pipeline with big potential, would you wait until price increases of would you start to buy as much as you can whilst you can?
Thanks Fadec for your response, just curious as you seem to know your subject matter; (along with many others on this board) Which area in your opinion is Sar key strength, in terms of the highest value commercial outcome.
I have set mine too but knowing the brokers they will lend them out anyway and only care about it once they have been found out. The main risk they have is if a big pharma or II starts aggressively buying them then someone will get caught short. Hence why they want to keep it below 3p